Wang W, et al. - In this study involving patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD), researchers examined the value of monitoring miR-92a. A total of 40 ACS patients with a history of CHD and diabetes while the onset time of diabetes preceded that of CHD by > 2 years were enrolled as the diabetes ACS (DACS) group. In addition, 40 ACS patients with a definite diagnosis of CHD for > 2 years and no history of T2DM were enrolled as the chronic CHD with ACS (CACS) group. According to findings, the miR-92a levels in the DACS group were significantly higher than those in the CACS and CHD groups. In CHD patients with T2DM, an elevated circulating miR-92a level was related to an increased risk of ACS. The miR-92a level, especially in combination with elevated systolic blood pressure and glycosylated hemoglobin, can, therefore, be helpful in the detection of ACS in patients with T2DM.